New drug CIT-013 tested for safety in small human trial
NCT ID NCT07499908
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 1 trial will test the safety and tolerability of a drug called CIT-013 in 10 healthy adults. Participants receive either CIT-013 or a placebo by injection under the skin. The study is double-blind, meaning neither participants nor researchers know who gets the real drug. Since this is an early-stage trial in healthy people, it does not aim to treat any disease.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- CIT-013
- What could go wrong
- This is a very early phase 1 trial with only 10 healthy volunteers, so it cannot yet show any treatment effect. The main goal is safety, not efficacy.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY ADULT are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
ICON
Groningen, Netherlands
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new antibody tame the Body's allergic alarm system?
- Fingerprint sweat could replace oral swabs for drug testing
- Wearable tech puts hormone health to the test
- Can a better hazmat suit keep first responders safer and more effective?
- Home video tracking may expose the gap between clinic walking and real-world walking after stroke
- Avocado at breakfast: a secret weapon for blood sugar and fullness?